I think you misread the numbers.
If someone was willing to invest $11,000,000 in AMBS at the current share price I would consider that to be great news.
Additional "orphan indications" for MANF along with "LymPro".
Tremendous upside from here.
"The results of this study together with the literature on MANF warrant a further development of this growth factor for the treatment of PD. While the path forward is facilitated by experience gained in the GDNF development, MANF, based on its different and unexploited mechanism of action, offers a promising new approach towards therapy of PD."
Final report required for the grant confirmed that MANF is more effective than GDNF.
It depends on when the next p.r. is issued.
Check out who's on the company's advisory board on the company's website.
Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is a strong supporter of the company. "The next Amgen in its infancy".
Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on the company's advisory board.
The company's drug, MANF, could be worth billions.